Pomalidomide: Comparison of different dosages and schedules of drug

Pomalidomide 2 mg/d on 28 Days/28 Day Cycle

Pomalidomide 4 mg/d on 21 Days/28 Day Cycle

Total

Sex: Female, Male

Immunoglobulin Heavy chain (IgH) type

Immunoglobulin Light chain (IgL) type

serum beta 2 microglobulin

serum albumin

lines of prior therapy

Deletion of chromosome 17p

Chromosome 1q abnormalities

Monosomy 13 on molecular cytogenics or deletion of 13q on fluorescence in situ hybridization (FISH) cytogenics

Deletion chromosome 13

Lenalidomide (Len) as most recent therapy

Resistance to prior therapy-Len refractory

Resistance to prior therapy-Len+bortezomib refractory

All partial and complete responses must be confirmed with another efficacy assessment in no less than 4 weeks apart.

Percentage of Participants With Response, Analyzed Per International Myeloma Working Group Response Criteria

Correlation to be determined upon completion of study treatment

To Compare the Effect of Continuous Versus Intermittent Regimens on F Actin Polymerization in Peripheral Blood Mononuclear Cells and Activation of Tumor Antigen-specific T Cells, as Well as Innate Lymphocytes (Natural Killer or Natural Killer T Cells).

Research bone marrow aspirate is obtained to assess response (optional, but recommended), and to document complete remission, if applicable. Correlation to be determined upon completion of study treatment

To Correlate Drug Induced Changes in F Actin Polymerization With Adverse Effects and Clinical Responses.

To Correlate Drug Induced Changes in F Actin With Cytokine Profile.

Overall Study

Madhav Dhodapkar, M.D.

Multiple Myeloma

Comparison of different dosages and schedules of drug

Pomalidomide

Yale University

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

Celgene Corporation

Chronic Myeloproliferative Disorders

Secondary Myelofibrosis

cyclophosphamide

prednisone

thalidomide

immunohistochemistry staining method

laboratory biomarker analysis

biopsy

Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide ("TPC") in the Therapy of Myelofibrosis With Myeloid Metaplasia (MMM)

metaplasia/väsimus

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus